Cutaneous  ||| S:0 E:10 ||| JJ
vasculitis  ||| S:10 E:21 ||| NN
and  ||| S:21 E:25 ||| CC
their  ||| S:25 E:31 ||| PRP$
differential  ||| S:31 E:44 ||| JJ
diagnoses  ||| S:44 E:54 ||| JJ
Vasculitis  ||| S:54 E:65 ||| NNP
is  ||| S:65 E:68 ||| VBZ
defined  ||| S:68 E:76 ||| VBN
as  ||| S:76 E:79 ||| IN
an  ||| S:79 E:82 ||| DT
inflammatory  ||| S:82 E:95 ||| JJ
cell  ||| S:95 E:100 ||| NN
infiltration  ||| S:100 E:113 ||| NNS
and  ||| S:113 E:117 ||| CC
destruction  ||| S:117 E:129 ||| NN
of  ||| S:129 E:132 ||| IN
blood  ||| S:132 E:138 ||| NN
vessels  ||| S:138 E:146 ||| NNS
identified  ||| S:146 E:157 ||| VBN
upon  ||| S:157 E:162 ||| IN
histologic  ||| S:162 E:173 ||| JJ
examination ||| S:173 E:184 ||| NN
.  ||| S:184 E:186 ||| .
Cutaneous  ||| S:186 E:196 ||| JJ
manifestations  ||| S:196 E:211 ||| NNS
are  ||| S:211 E:215 ||| VBP
frequent  ||| S:215 E:224 ||| JJ
during  ||| S:224 E:231 ||| IN
the  ||| S:231 E:235 ||| DT
course  ||| S:235 E:242 ||| NN
of  ||| S:242 E:245 ||| IN
many  ||| S:245 E:250 ||| JJ
systemic  ||| S:250 E:259 ||| JJ
vasculitis ||| S:259 E:269 ||| NN
.  ||| S:269 E:271 ||| .
Lesions  ||| S:271 E:279 ||| NNS
are  ||| S:279 E:283 ||| VBP
often  ||| S:283 E:289 ||| RB
not  ||| S:289 E:293 ||| RB
specific ||| S:293 E:301 ||| JJ
,  ||| S:301 E:303 ||| ,
the  ||| S:303 E:307 ||| DT
most  ||| S:307 E:312 ||| RBS
frequent  ||| S:312 E:321 ||| JJ
being  ||| S:321 E:327 ||| VBG
palpable  ||| S:327 E:336 ||| JJ
purpura ||| S:336 E:343 ||| NN
.  ||| S:343 E:345 ||| .
They  ||| S:345 E:350 ||| PRP
may  ||| S:350 E:354 ||| MD
be  ||| S:354 E:357 ||| VB
the  ||| S:357 E:361 ||| DT
first  ||| S:361 E:367 ||| JJ
and  ||| S:367 E:371 ||| CC
only  ||| S:371 E:376 ||| RB
manifestation  ||| S:376 E:390 ||| VBN
of  ||| S:390 E:393 ||| IN
the  ||| S:393 E:397 ||| DT
disease  ||| S:397 E:405 ||| NN
or  ||| S:405 E:408 ||| CC
be  ||| S:408 E:411 ||| VB
a  ||| S:411 E:413 ||| DT
part  ||| S:413 E:418 ||| NN
of  ||| S:418 E:421 ||| IN
a  ||| S:421 E:423 ||| DT
systemic  ||| S:423 E:432 ||| JJ
condition ||| S:432 E:441 ||| NN
.  ||| S:441 E:443 ||| .
Histology  ||| S:443 E:453 ||| NNP
is  ||| S:453 E:456 ||| VBZ
mandatory  ||| S:456 E:466 ||| JJ
to  ||| S:466 E:469 ||| TO
confirm  ||| S:469 E:477 ||| VB
the  ||| S:477 E:481 ||| DT
diagnosis  ||| S:481 E:491 ||| NN
of  ||| S:491 E:494 ||| IN
vasculitis  ||| S:494 E:505 ||| VBG
to  ||| S:505 E:508 ||| TO
avoid  ||| S:508 E:514 ||| VB
a  ||| S:514 E:516 ||| DT
delayed  ||| S:516 E:524 ||| JJ
and  ||| S:524 E:528 ||| CC
inappropriate  ||| S:528 E:542 ||| JJ
diagnosis  ||| S:542 E:552 ||| NN
that  ||| S:552 E:557 ||| WDT
could  ||| S:557 E:563 ||| MD
lead  ||| S:563 E:568 ||| VB
to  ||| S:568 E:571 ||| TO
improper  ||| S:571 E:580 ||| JJ
management ||| S:580 E:590 ||| NN
.  ||| S:590 E:592 ||| .
Cutaneous  ||| S:592 E:602 ||| JJ
histology  ||| S:602 E:612 ||| NN
gave  ||| S:612 E:617 ||| VBD
some  ||| S:617 E:622 ||| DT
data  ||| S:622 E:627 ||| NNS
that  ||| S:627 E:632 ||| WDT
may  ||| S:632 E:636 ||| MD
help  ||| S:636 E:641 ||| VB
to  ||| S:641 E:644 ||| TO
classify  ||| S:644 E:653 ||| VB
the  ||| S:653 E:657 ||| DT
vasculitis  ||| S:657 E:668 ||| NN
without  ||| S:668 E:676 ||| IN
determining  ||| S:676 E:688 ||| VBG
precisely  ||| S:688 E:698 ||| RB
its  ||| S:698 E:702 ||| PRP$
type ||| S:702 E:706 ||| NN
.  ||| S:706 E:708 ||| .
A  ||| S:708 E:710 ||| DT
histological  ||| S:710 E:723 ||| JJ
examination  ||| S:723 E:735 ||| NN
of  ||| S:735 E:738 ||| IN
all  ||| S:738 E:742 ||| DT
other  ||| S:742 E:748 ||| JJ
skin  ||| S:748 E:753 ||| NN
lesions  ||| S:753 E:761 ||| NN
is  ||| S:761 E:764 ||| VBZ
necessary ||| S:764 E:773 ||| JJ
.  ||| S:773 E:775 ||| .
The  ||| S:775 E:779 ||| DT
result  ||| S:779 E:786 ||| NN
of  ||| S:786 E:789 ||| IN
the  ||| S:789 E:793 ||| DT
biopsy  ||| S:793 E:800 ||| NN
has  ||| S:800 E:804 ||| VBZ
to  ||| S:804 E:807 ||| TO
be  ||| S:807 E:810 ||| VB
correlated  ||| S:810 E:821 ||| VBN
to  ||| S:821 E:824 ||| TO
DIF  ||| S:824 E:828 ||| NNP
data ||| S:828 E:832 ||| NNS
,  ||| S:832 E:834 ||| ,
medical  ||| S:834 E:842 ||| JJ
history ||| S:842 E:849 ||| NN
,  ||| S:849 E:851 ||| ,
physical  ||| S:851 E:860 ||| JJ
examination ||| S:860 E:871 ||| NN
,  ||| S:871 E:873 ||| ,
laboratory  ||| S:873 E:884 ||| NN
and  ||| S:884 E:888 ||| CC
radiological  ||| S:888 E:901 ||| JJ
findings  ||| S:901 E:910 ||| NNS
leading  ||| S:910 E:918 ||| VBG
to  ||| S:918 E:921 ||| TO
the  ||| S:921 E:925 ||| DT
correct  ||| S:925 E:933 ||| JJ
diagnosis  ||| S:933 E:943 ||| NN
and  ||| S:943 E:947 ||| CC
effective  ||| S:947 E:957 ||| JJ
treatment.In  ||| S:957 E:970 ||| CD
this  ||| S:970 E:975 ||| DT
review ||| S:975 E:981 ||| NN
,  ||| S:981 E:983 ||| ,
we  ||| S:983 E:986 ||| PRP
discuss  ||| S:986 E:994 ||| VB
the  ||| S:994 E:998 ||| DT
diagnosis  ||| S:998 E:1008 ||| NN
of  ||| S:1008 E:1011 ||| IN
cutaneous  ||| S:1011 E:1021 ||| JJ
vasculitis  ||| S:1021 E:1032 ||| NNS
( ||| S:1032 E:1033 ||| -LRB-
CV ||| S:1033 E:1035 ||| NNP
)  ||| S:1035 E:1037 ||| -RRB-
and  ||| S:1037 E:1041 ||| CC
the  ||| S:1041 E:1045 ||| DT
pitfalls  ||| S:1045 E:1054 ||| NNS
related  ||| S:1054 E:1062 ||| VBN
to  ||| S:1062 E:1065 ||| TO
the  ||| S:1065 E:1069 ||| DT
cutaneous  ||| S:1069 E:1079 ||| JJ
pathology ||| S:1079 E:1088 ||| NN
.  ||| S:1088 E:1090 ||| .
We  ||| S:1090 E:1093 ||| PRP
also  ||| S:1093 E:1098 ||| RB
describe  ||| S:1098 E:1107 ||| VB
the  ||| S:1107 E:1111 ||| DT
essential  ||| S:1111 E:1121 ||| JJ
features  ||| S:1121 E:1130 ||| NNS
of  ||| S:1130 E:1133 ||| IN
the  ||| S:1133 E:1137 ||| DT
major  ||| S:1137 E:1143 ||| JJ
categories  ||| S:1143 E:1154 ||| NNS
of  ||| S:1154 E:1157 ||| IN
skin  ||| S:1157 E:1162 ||| NN
vasculitis ||| S:1162 E:1172 ||| NN
.  ||| S:1172 E:1174 ||| .
